PropThink

About the Author PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market coverage and actionable research to PropThink Premium and Premium Plus subscribers.

Gilead Tops Expectations And Raises Guidance (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) blew past analyst expectations in the first quarter, reporting $7.

Pacira Pharmaceuticals Inc (PCRX) Crumbles with Earnings, Removal of Sales Guidance

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) took it on the chin at Thursday’s open as the company completely removed sales guidance for its only marketed …

Celladon Corp’s Sweeping Impact on Biotech (CLDN)

It’s happened – the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon Corp (NASDAQ:CLDN) reported on Sunday …

Acquisition Limbo Begins for Three Major Generic Drugmakers: TEVA, MYL, PRGO

Teva Pharmaceuticals Industries Ltd (ADR) (NYSE:TEVA) has made an official and unsolicited bid for rival generic drugmaker Mylan NV (NASDAQ:MYL), offering $82/share in a combination …

Aduro Bio Tech Inc is the Latest and Hottest Oncology IPO (ADRO)

Aduro Bio Tech Inc (NASDAQ:ADRO) begins trading on Wednesday morning at 10:25 ET having completed a $119 million IPO that values the immunotherapy …

Dyax Corp. Adds Over $1 Billion in Market Value on Early Drug Results

Dyax Corp. (NASDAQ:DYAX) saw a gain of over 40% in pre-market trading Wednesday with the release of phase 1b results for DX-2930, an …

Your Guide to Biotech M&A Monday

Some biopharma business development teams had a sleepless weekend. Four healthcare-related acquisitions were announced in quick succession on Monday morning, totaling about $18 billion …

More Details Emerge on Medivation’s XTANDI in Prostate Cancer

Medivation Inc (NASDAQ:MDVN) issued a joint statement with Astellas Pharma on Monday announcing detailed results for the use of enzalutamide in castration-resistant prostate …

A Roundup of Our Top Stories in Healthcare From the Week

One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …

Biogen Idec Inc Meets Expectations With Early Alzheimer’s Drug

Even after adding $30 billion in market value over the last four months, shares of Biogen Idec Inc (NASDAQ:BIIB) moved higher on Friday morning with the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts